Measurements of birth defect prevalence: Which is most useful as a comparator group for pharmaceutical pregnancy registries?

Birth Defects Research Part A - Clinical and Molecular Teratology

Volumn 85, Issue 7, 2009, Pages 611-620

  Scheuerle, Angela ^a   Vannappagari, Vani X ^b   Miller, Mary K ^c  

^a Tesserae Genetics Texas   (United States)

^b GLAXOSMITHKLINE   (United States)

^c GENENTECH INC   (United States)

Author keywords

Birth defect; Birth defect prevalence; Pregnancy registry

Indexed keywords

ACCURACY; BIRTH DEFECT; COMPARATIVE STUDY; DATA BASE; HEALTH CARE; HEALTH PROGRAM; HUMAN; INFORMATION PROCESSING; MEASUREMENT; METHODOLOGY; NONHUMAN; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REGISTER; REVIEW; STATISTICAL ANALYSIS; TERATOGENICITY;

CONGENITAL ABNORMALITIES; DATABASES, FACTUAL; FEMALE; HUMANS; POPULATION SURVEILLANCE; PREGNANCY; PREGNANCY COMPLICATIONS; PUBLIC HEALTH; PUBLIC HEALTH INFORMATICS; REGISTRIES;

EID: 67651180665     PISSN: 15420752     EISSN: 15420760     Source Type: Journal    
DOI: 10.1002/bdra.20572     Document Type: Review

References (35)

1. Andrews EB, Tennis P. 2007. Promise and pitfalls of administrative data in evaluating pregnancy outcomes. Pharmacoepidemiol Drug Safety 16:1181-1183. (Pubitemid 350120641)
2. Antiretroviral Pregnancy Registry. 2008. International interim report for 1 January 1989 through 31 January 2008. Available at: http://www.apregistry. com/who.htm. Accessed November 2, 2008.
3. California Birth Defects Monitoring Program. The impact of birth defects: California. Available at: http://www.cbdmp.org/gd-california.htm. Accessed November 2, 2008.
4. Canfield MA, Honein MA, Yuskiv N, et al. 2006. National estimates and race/ethnic-specific variation of selected birth defects in the United States, 1999-2001. Birth Defects Res A Clin Mol Teratol 76:747-756 (Pubitemid 44777830)
5. Centers for Disease Control and Prevention. 2003. HIPAA Privacy Rule and Public Health: Guidance from CDC and the U.S. Department of Health and Human Services. MMWR Morb Motal Wkly Rep 52(S-1): 1-12.
6. Charlton RA, Cunnington MC, de Vries CS, Weil JG. 2008. Data resources for investigating drug exposure during pregnancy and associated outcomes: the general practice research database (GPRD) as an alternative to pregnancy registries. Drug Saf 31:39-51.
7. Colorado Department of Public Health and Environment. Colorado responds to children with special needs. Available at: http://www.cdphe.state.co.us/dc/ crcsn/aboutus.html. Accessed November 2, 2008.
8. Correa A, Cragan JD, Kucik ME, et al. 2007. Metropolitan Atlanta congenital defects program: 40th anniversary edition surveillance report. Reporting birth defects surveillance data 1968-2003. Birth Defects Res A Clin Mol Teratol 79:65-186. Erratum published in Birth Defects Res A Clin Mol Teratol 2008; 80:41-62.
9. DeFrances CJ, Hall MJ. 2007. 2005 National Hospital Discharge Survey. National Center for Health Statistics. Advance Data from Vital and Health Statistics, No.385. Published by the Centers for Disease Control and Prevention, July 12, 2007.
10. Duke W, Alverson CJ, Correa A. 2007. Fetal death certificates as a source of surveillance data for stillbirths with birth defects. Public Health Res 122:664-669..
11. EUROCAT Registries. Population definition, geographical area, stillbirth definition and maximum age at diagnosis (Report 8 Appendix 7). Available at: http://www.eurocat.ulster.ac.uk/memberreg/. Accessed October 12, 2008.
12. Eurocat: http://www.eurocat.ulster.ac.uk/index.html. Last accessed October 12, 2008.
13. Eurocat Cases and prevalence per 10,000 births for All Full Member Registries from 1980-2006: http://www.bio-medical.co.uk/eurocatlive/ results1.cgi. Last accessed November 2, 2008.
14. Food and Drug Administration. 2002a. Guidance for industry: establishing pregnancy exposure registries. Washington, DC: U.S. Department of Health and Human Services. pp. 2-3. http://www.bio-medical. co.uk/eurocatlive
15. Food and Drug Administration. 2002b. Guidance for industry: establishing pregnancy exposure registries. Washington, DC: U.S. Department of Health and Human Services. pp. 8-9.
16. Food and Drug Administration. 2002c. Guidance for industry: establishing pregnancy exposure registries. Washington, DC: U.S. Department of Health and Human Services. p. 14.
17. Food and Drug Administration. 2002d. Guidance for industry: establishing pregnancy exposure registries. Washington, DC: U.S. Department of Health and Human Services. p. 8.
18. Food and Drug Administration Office of Women's Health. List of pregnancy exposure registries. Washington, DC: U.S. Department of Health and Human Services. Available at: www.fda.gov/womens/ registries/ registries.html. Last accessed November 8, 2008.
19. Honein MA, Paulozzi LJ. 1999. Birth defects surveillance: assessing the "gold standard". Am J Public Health 89:1238-1240.
20. Honein MA, Lindstrom JA, Kweder SL. 2007. Can we ensure the safe use of known human teratogens?: The iPLEDGE test case. Drug Saf 30:5-15.
21. International Clearinghouse for Birth Defects Surveillance and Research. 2006. Annual Report: 2006 with data for 2004. Rome: International Centre on Birth Defects.
22. International Clearinghouse for Birth Defects Survelliance and Research. Programme descriptions. Available at: http://www.icbdsr.org/page.asp? p512919&l51. Accessed October 12, 2008.
23. Langlois PH, Scheuerle A. 2007. Using registry data to suggest which birth defects may be more susceptible to artifactual clusters and trends. Birth Defects Res A Clin Mol Teratol 79:798-805. (Pubitemid 350271828)
24. Mai CT, Law DJ, Mason CA, et al. 2007. Collection, use, and protection of population-based birth defects surveillance data in the United States. Birth Defects Res A Clin Mol Teratol 79:811-814.
25. Martin JA, Hamilton BE, Sutton PD, et al. 2007. Births: final data for 2005. Natl Vital Stat Rep 56:3-4.
26. Merck. 2006. Eighth annual report on exposure during pregnancy from the Merck Pregnancy Registry for Singulair (montelukast sodium) covering the period from U.S. approval (February 20, 1998) through July 2006. Whitehouse Station, New Jersey: Merck.
27. National Birth Defects Prevention Network. 2007a. State Birth Defects Surveillance Program Directory. Birth Defects Res A Clin Mol Teratol 79:815-873.
28. National Birth Defects Prevention Network. 2007b. Congenital malformations surveillance report: population-based birth defects surveillance data from selected states, 2000-2004. Birth Defects Res A Clin Mol Teratol 79:874-942.
29. National Birth Defects Prevention Network Mission Statement. www.nbdpn.org. Last accessed July 7, 2008.
30. New York State Department of Health Congenital Malformations Registry. Summary report: statistical summary of children born 2002-2004 and diagnosed through 2006. Available at: http://www.health.state. ny.us/diseases/congenital- malformations/cmrhome.htm. Accessed November 2, 2008.
31. Organization of Teratology Information Specialists. Available at: http:// www.otispregnancy.org. Accessed December 10, 2008.
32. Texas Birth Defects Registry. 2008. Report of defects among 1999-2004 deliveries. Available at: http://www.dshs.state.tx.us/birthdefects/ Data/annl99-04.shtm. Accessed November 2, 2008.
33. Verity C, Nicoll A. 2002. Consent, confidentiality, and the threat to public health surveillance. BMJ 324:1210-1213.
34. Wier ML, Yoshida CK, Odouli R, et al. 2006. Congenital anomalies associated with autismspectrum disorder.DevMed Child Neurol 48:500-507.
35. Zeldis JB, Williams BA, Thomas SD, Elsayed ME. 1999. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 21:319-330.